COCH Form 4 reports purchase transactions

Lucas Brent T. reported open-market purchase transactions in a Form 4 filing for COCH.

(High)

(Positive)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Lucas Brent T. reported open-market purchase transactions in a Form 4 filing for COCH. The filing lists transactions totaling 162,500 shares at a weighted average price of $0.40 per share. Following the reported transactions, holdings were 37,500 shares.

Insider Trade Summary

Net Buyer: 162,500 shares

Net Buy 6 txns

Insider Lucas Brent T.

Role Chief Executive Officer

Bought 162,500 shs ($25K)

Type	Security	Shares	Price	Value
Purchase	Warrant (right to buy)	37,500	$0.00	$0.00
Purchase	Warrant (right to buy)	62,500	$0.00	$0.00
Purchase	Class A Common Stock	62,500	$0.40	$25K
holding	Stock Option (right to buy)	--	--	--
holding	Stock Option (right to buy)	--	--	--
holding	Warrant (right to buy)	--	--	--

Holdings After Transaction: Warrant (right to buy) — 210,987 contracts for 110,987 underlying shares (Direct); Class A Common Stock — 297,090 shares (Direct); Stock Option (right to buy) — 1,079,749 contracts (Direct)

Footnotes (6)

F1. Options to purchase 659,811 shares vest on 10/15/2023, and 219,938 shares vest pro rata on the 15th of each month thereafter for 36 consecutive months.
F2. Options to purchase 50,000 shares vest on 2/5/2027, and 150,000 shares vest pro rata on the 5th of each month thereafter for 36 consecutive months.
F3. Fully exercisable.
F4. Exercisable upon shareholder approval of the issuance of shares of Class A Common Stock underlying the warrants.
F5. The Series A-1 Warrants expire on the earlier of (i) two years from the initial exercise date and (ii) 30 days after the date on which the Company announces that it has submitted a Premarket Approval Application to the Food and Drug Administration (FDA) for its Acclaim CI Device.
F6. The Series A-2 Warrants expire on the earlier of (i) five years from the initial exercise date and (ii) 30 days after the date on which the Company announces that it has received FDA approval for its Acclaim CI Device.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did Envoy Medical (COCH) report on February 12, 2026?

Envoy Medical reported that CEO and director Brent T. Lucas bought 62,500 Class A Common shares at $0.40 each and acquired Series A-1 and A-2 warrants on 37,500 and 62,500 shares, respectively, all in directly owned accounts.

How many Envoy Medical (COCH) shares does the CEO own after this Form 4?

After the reported transaction, CEO Brent T. Lucas directly owns 297,090 shares of Envoy Medical Class A Common Stock, in addition to multiple option grants and warrants covering further shares as detailed in the derivative securities table.

At what price did the Envoy Medical (COCH) CEO buy common stock in this filing?

Brent T. Lucas purchased 62,500 shares of Envoy Medical Class A Common Stock at $0.40 per share in an open-market or private transaction, according to the Form 4 transaction code P and related pricing disclosure.

What are the key terms of the Envoy Medical (COCH) Series A-1 warrants reported?

The Series A-1 warrants held by Brent T. Lucas are exercisable at $0.40 per share after shareholder approval of the underlying share issuance and expire the earlier of two years from initial exercise or 30 days after the company announces submission of a Premarket Approval Application for its Acclaim CI Device.

What are the terms of the Envoy Medical (COCH) Series A-2 warrants in this Form 4?

The Series A-2 warrants reported for Brent T. Lucas are exercisable at $0.40 per share following shareholder approval of the related share issuance and expire the earlier of five years from initial exercise or 30 days after the company announces it has received FDA approval for its Acclaim CI Device.

What stock option positions for Envoy Medical (COCH) does the CEO report holding?

Brent T. Lucas reports directly holding stock options on 879,749 shares, with specified vesting beginning October 15, 2023, and options on 200,000 shares with vesting starting February 5, 2027, each vesting over 36 months as described in the footnotes.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 02/17/2026 - 04:45 PM EST

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lucas Brent T.

(Last)

(First)

(Middle)

C/O 4875 WHITE BEAR PARKWAY

(Street)

WHITE BEAR LAKE

55110

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Envoy Medical, Inc. [ COCH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/12/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Class A Common Stock	02/12/2026		P		62,500	A	$0.4	297,090	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (right to buy)	$2.4							⁽¹⁾	10/15/2033	Class A Common Stock	879,749		879,749	D
Stock Option (right to buy)	$0.53							⁽²⁾	02/05/2036	Class A Common Stock	200,000		200,000	D
Warrant (right to buy)	$11.5							⁽³⁾	09/29/2028	Class A Common Stock	110,987		110,987	D
Warrant (right to buy)	$0.4	02/12/2026		P		37,500		⁽⁴⁾	⁽⁵⁾	Class A Common Stock	37,500	$0	37,500	D
Warrant (right to buy)	$0.4	02/12/2026		P		62,500		⁽⁴⁾	⁽⁶⁾	Class A Common Stock	62,500	$0	62,500	D

Explanation of Responses:

1. Options to purchase 659,811 shares vest on 10/15/2023, and 219,938 shares vest pro rata on the 15th of each month thereafter for 36 consecutive months.

2. Options to purchase 50,000 shares vest on 2/5/2027, and 150,000 shares vest pro rata on the 5th of each month thereafter for 36 consecutive months.

3. Fully exercisable.

4. Exercisable upon shareholder approval of the issuance of shares of Class A Common Stock underlying the warrants.

5. The Series A-1 Warrants expire on the earlier of (i) two years from the initial exercise date and (ii) 30 days after the date on which the Company announces that it has submitted a Premarket Approval Application to the Food and Drug Administration (FDA) for its Acclaim CI Device.

6. The Series A-2 Warrants expire on the earlier of (i) five years from the initial exercise date and (ii) 30 days after the date on which the Company announces that it has received FDA approval for its Acclaim CI Device.

	s/ Andrew Nick as Attorney-in-Fact for Brent Lucas pursuant to Power of Attorney previously filed.	02/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR